Learn more about ibrutinib/ibrutinib: action, efficacy and safety

Ibrutinib/Ibrutinib, a revolutionary oral targeted drug, has shown excellent results in the treatment of a variety of hematological malignancies, especially chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM) and chronic graft-versus-host disease (cGVHD). It belongs to the drug class of Bruton's tyrosine kinase (BTK) inhibitors.

The core principle of ibrutinib is to precisely inhibit the activity ofBTK and cut off the signal transduction pathway, thereby effectively interfering with the growth and survival of cancer cells. Since BTK plays a crucial role in the development and function of B cells, inhibition of this target could achieve effective control of B cell-related malignancies.

Ibrutinib has excellent oral bioavailability, which means that patients can quickly absorb the drug through oral administration and achieve the blood concentration required for treatment. Data from multiple clinical trials have confirmed that ibrutinib has shown impressive efficacy in the treatment of various indications. For example, in clinical studies of relapsed/refractory CLL, the overall response rate was as high as approximately 71%; and in trials of relapsed/refractory mantle cell lymphoma, approximately 70% of patients achieved partial or complete response. In addition, ibrutinib has also demonstrated significant therapeutic effects for a variety of other indications, such as relapsed/refractory diffuse large B-cell lymphoma, Waldenstrom macroglobulinemia, and relapsed/refractory follicular lymphoma.

As an important part of a long-term treatment plan, patients need to take ibrutinib regularly every day. During treatment, doctors will conduct regular monitoring and evaluation to ensure the safety and effectiveness of the drug. Although the side effects of ibrutinib are relatively mild and can be well tolerated by most patients, there are still some potential risks and warnings that need to be paid attention to, such as bleeding, infection, arrhythmia, hypertension, cytopenia, etc. In addition, pregnant and lactating women should consult a doctor before use to avoid potential effects on the fetus or baby.